Chemed Stock Forecast, Price & News

Chemed (NYSE:CHE) Frequently Asked Questions

Is Chemed a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Chemed stock.
View analyst ratings for Chemed or view top-rated stocks.

How has Chemed's stock price been impacted by COVID-19 (Coronavirus)?

Chemed's stock was trading at $414.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CHE shares have increased by 15.7% and is now trading at $478.86.
View which stocks have been most impacted by COVID-19.

When is Chemed's next earnings date?

Chemed is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Chemed.

How were Chemed's earnings last quarter?

Chemed Co. (NYSE:CHE) announced its earnings results on Thursday, October, 28th. The company reported $5.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $4.49 by $0.57. The business earned $538.67 million during the quarter, compared to analyst estimates of $531.87 million. Chemed had a trailing twelve-month return on equity of 35.68% and a net margin of 14.43%. The business's quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.86 EPS.
View Chemed's earnings history.

How often does Chemed pay dividends? What is the dividend yield for Chemed?

Chemed announced a quarterly dividend on Friday, November 5th. Shareholders of record on Monday, November 15th will be paid a dividend of $0.36 per share on Monday, December 6th. This represents a $1.44 annualized dividend and a dividend yield of 0.30%. The ex-dividend date is Friday, November 12th.
View Chemed's dividend history.

Is Chemed a good dividend stock?

Chemed pays an annual dividend of $1.44 per share and currently has a dividend yield of 0.30%. Chemed has been increasing its dividend for 14 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Chemed is 7.57%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemed will have a dividend payout ratio of 7.40% next year. This indicates that Chemed will be able to sustain or increase its dividend.
View Chemed's dividend history.

What guidance has Chemed issued on next quarter's earnings?

Chemed updated its FY 2021 earnings guidance on Thursday, November, 4th. The company provided EPS guidance of $19.000-$19.200 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $17.910. The company issued revenue guidance of -.

What price target have analysts set for CHE?

2 equities research analysts have issued twelve-month target prices for Chemed's stock. Their forecasts range from $580.00 to $609.00. On average, they anticipate Chemed's stock price to reach $594.50 in the next year. This suggests a possible upside of 24.1% from the stock's current price.
View analysts' price targets for Chemed or view top-rated stocks among Wall Street analysts.

Who are Chemed's key executives?

Chemed's management team includes the following people:

• Kevin J. McNamara, President, Chief Executive Officer & Director (LinkedIn Profile)
• David Patrick Williams, Chief Financial Officer & Executive Vice President
• Spencer S. Lee, Executive Vice President
• Nicholas M. Westfall, Executive Vice President
• Thomas C. Hutton, Director & Vice President

What is Kevin J. McNamara's approval rating as Chemed's CEO?

1 employees have rated Chemed CEO Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among Chemed's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Chemed's key competitors?

Some companies that are related to Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), R1 RCM (RCM), AMN Healthcare Services (AMN), Amedisys (AMED), LHC Group (LHCG), CorVel (CRVL), MEDNAX (MD), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of CHE's competitors.

What other stocks do shareholders of Chemed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

What is Chemed's stock symbol?

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Who are Chemed's major shareholders?

Chemed's stock is owned by a number of institutional and retail investors. Top institutional investors include Copeland Capital Management LLC (0.86%), Riverbridge Partners LLC (0.63%), Trinity Street Asset Management LLP (0.27%), Fenimore Asset Management Inc. (0.17%), Miracle Mile Advisors LLC (0.04%) and State of Alaska Department of Revenue (0.04%). Company insiders that own Chemed stock include Andrea R Lindell, Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee and Thomas P Rice.
View institutional ownership trends for Chemed.

Which institutional investors are selling Chemed stock?

CHE stock was sold by a variety of institutional investors in the last quarter, including Trinity Street Asset Management LLP, State of Alaska Department of Revenue, Crossmark Global Holdings Inc., and Miracle Mile Advisors LLC. Company insiders that have sold Chemed company stock in the last year include Donald E Saunders, Kevin J Mcnamara, Nicholas Michael Westfall, Spencer S Lee, and Thomas P Rice.
View insider buying and selling activity for Chemed or view top insider-selling stocks.

Which institutional investors are buying Chemed stock?

CHE stock was purchased by a variety of institutional investors in the last quarter, including Fenimore Asset Management Inc., Copeland Capital Management LLC, Riverbridge Partners LLC, LRT Capital Management LLC, IFP Advisors Inc, Exchange Traded Concepts LLC, and Spire Wealth Management.
View insider buying and selling activity for Chemed or or view top insider-buying stocks.

How do I buy shares of Chemed?

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemed's stock price today?

One share of CHE stock can currently be purchased for approximately $478.86.

How much money does Chemed make?

Chemed has a market capitalization of $7.53 billion and generates $2.08 billion in revenue each year. The company earns $319.47 million in net income (profit) each year or $19.03 on an earnings per share basis.

How many employees does Chemed have?

Chemed employs 15,544 workers across the globe.

When was Chemed founded?

Chemed was founded in 1970.

What is Chemed's official website?

The official website for Chemed is www.chemed.com.

Where are Chemed's headquarters?

Chemed is headquartered at 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202.

How can I contact Chemed?

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at (513) 762-6690 or via fax at 513-762-6590.